Overcoming of P-glycoprotein-mediated multidrug resistance of tumors in vivo by drug combinations

Synergy

Volumn 1, Issue 1, 2014, Pages 44-58

  Saeed, Mohamed ^a   Zeino, Maen ^a   Kadioglu, Onat ^a   Volm, Manfred ^b   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

ABC transporters; Chemotherapy; P glycoprotein; Reversal of resistance

Indexed keywords

ACRIVASTINE; ANTINEOPLASTIC AGENT; CLOMIPRAMINE; CRIZOTINIB; DIPYRIDAMOLE; DOCETAXEL; DOFEQUIDAR; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; FLUOXETINE; GLYCOPROTEIN P INHIBITOR; MACROGOL STEARATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; NERATINIB; PACLITAXEL; PANTOPRAZOLE; PYRONARIDINE; SARACATINIB; SDZ 280446; TAMOXIFEN; TARIQUIDAR; TETRAHYDROISOQUINOLINE DERIVATIVE; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCRISTINE; ZOSUQUIDAR;

BREAST CANCER; COLON CANCER; COMBINATION CHEMOTHERAPY; DOWN REGULATION; HUMAN; LEUKEMIA; LUNG CANCER; MELANOMA; MULTIDRUG RESISTANCE; NEOPLASM; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR XENOGRAFT; UPREGULATION; UTERINE CERVIX CANCER;

ANIMALIA; MURINAE;

EID: 84921832750     PISSN: 22137130     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.synres.2014.07.002     Document Type: Review

References (163)

1. Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003, 22:188-199.
2. Riordan J.R., Ling V. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 1979, 254:12701-12705.
3. Shen D.W., Fojo A., Chin J.E., Roninson I.B., Richert N., Pastan I., et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 1986, 232:643-645.
4. Roninson I.B., Chin J.E., Choi K.G., Gros P., Housman D.E., Fojo A., et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A 1986, 83:4538-4542.
5. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455:152-162.
6. Volm M., Bak M., Efferth T., Lathan B., Mattern J. Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4. Anticancer Res 1988, 8:531-535.
7. Volm M., Bak M., Efferth T., Mattern J. Induced multidrug resistance in murine leukemia L1210 and associated changes in a surface-membrane glycoprotein. J Cancer Res Clin Oncol 1989, 115:17-24.
8. Mattern J., Bak M., Volm M. Intrinsic and acquired multidrug resistance in human lung carcinomas grown in nude mice. Anticancer Res 1990, 10:177-180.
9. van de Vrie W., Marquet R.L., Stoter G., De Bruijn E.A., Eggermont A.M. In vivo model systems in P-glycoprotein-mediated multidrug resistance. Crit Rev Clin Lab Sci 1998, 35:1-57.
10. Efferth T., Osieka R. Clinical relevance of the MDR-1 gene and its gene product, P-glycoprotein, for cancer chemotherapy. Tumor Diagn Ther 1993, 14:238-243.
11. Schneider J., Bak M., Efferth T., Kaufmann M., Mattern J., Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989, 60:815-818.
12. Sauerbrey A., Zintl F., Volm M. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia. Br J Cancer 1994, 70:1144-1149.
13. Linn S.C., Giaccone G. MDR1/P-glycoprotein expression in colorectal cancer. Eur J Cancer 1995, 31A:1291-1294.
14. Kaye S.B. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 1998, 10(Suppl. 1):S15-S19.
15. Marie J.P., Legrand O. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol 1999, 457:1-9.
16. Pallis M., Turzanski J., Higashi Y., Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002, 43:1221-1228.
17. Clarke R., Leonessa F., Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol 2005, 32(6 Suppl. 7):S9-S15.
18. Efferth T. The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 2001, 1:45-65.
19. Gillet J.P., Efferth T., Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007, 1775:237-262.
20. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41:1967-1972.
21. Ford J.M., Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990, 42:155-199.
22. Volm M. Multidrug resistance and its reversal. Anticancer Res 1998, 18:2905-2917.
23. Molnár J., Engi H., Hohmann J., Molnár P., Deli J., Wesolowska O., et al. Reversal of multidrug resistance by natural substances from plants. Curr Top Med Chem 2010, 10:1757-1768.
24. Palmeira A., Sousa E., Vasconcelos M.H., Pinto M.M. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 2012, 19:1946-2025.
25. Eichhorn T., Efferth T. P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs. J Ethnopharmacol 2012, 141:557-570.
26. Abraham I., El Sayed K., Chen Z.S., Guo H. Current status on marine products with reversal effect on cancer multidrug resistance. Mar Drugs 2012, 10:2312-2321.
27. Volm M., Mattern J., Efferth T. P-Glykoprotein als Marker für Multidrug-Resistanz in Tumoren und Normalgewebe. Tumor Diagn Ther 1990, 11:189-197.
28. Tamaki A., Ierano C., Szakacs G., Robey R.W., Bates S.E. The controversial role of ABC transporters in clinical oncology. Essays Biochem 2011, 50:209-232.
29. Amiri-Kordestani L., Basseville A., Kurdziel K., Fojo A.T., Bates S.E. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Update 2012, 15:50-61.
30. Yu M., Ocana A., Tannock I.F. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?. Cancer Metastasis Rev 2013, 32:211-227.
31. Sharom F.J. The P-glycoprotein efflux pump: how does it transport drugs?. J Membr Biol 1997, 160:161-175.
32. Ferreira R.J., Ferreira M.J., dos Santos D.J. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J Chem Inf Model 2013, 53:1747-1760.
33. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012, 75:311-335.
34. Efferth T., Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets 2011, 12:122-132.
35. Bailey D.G., Dresser G., Arnold J.M. Grapefruit-medication interactions: forbidden fruit or avoidable consequences?. CMAJ 2013, 185:309-316.
36. Volm M., Pommerenke E.W., Efferth T., Löhrke H., Mattern J. Circumvention of multi-drug resistance in human kidney and kidney carcinoma in vitro. Cancer 1991, 67:2484-2489.
37. Efferth T., Volm M. Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. Oncology 1993, 50:303-308.
38. Efferth T., Volm M. Antibody-directed therapy of multidrug-resistant tumor cells. Med Oncol Tumor Pharmacother 1992, 9:11-19.
39. Pommerenke E.W., Sinn H., Volm M. Circumvention of doxorubicin-resistance in tumours by albumin-conjugated doxorubicin. Eur J Cancer 1995, 31A:283-284.
40. Markman J.L., Rekechenetskiy A., Holler E., Ljubimova J.Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 2013, 65:1866-1879.
41. Patel N.R., Pattni B.S., Abouzeid A.H., Torchilin V.P. Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev 2013, 65:1748-1762.
42. Chen Y., Chen H., Shi J. Inorganic nanoparticle-based drug codelivery nanosystems to overcome the multidrug resistance of cancer cells. Mol Pharm 2013, [Epub ahead of print].
43. Zhang Q., Li F. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles. Curr Pharm Des 2013, 19:6655-6666.
44. Alvarez-Salas L.M. Nucleic acids as therapeutic agents. Curr Top Med Chem 2008, 8:1379-1404.
45. Angart P., Vocelle D., Chan C., Walton S.P. Design of siRNA therapeutics from the molecular scale. Pharmaceuticals (Basel) 2013, 6:440-468.
46. Uchino K., Ochiya T., Takeshita F. RNAi therapeutics and applications of microRNAs in cancer treatment. Jpn J Clin Oncol 2013, 43:596-607.
47. Yang W.Q., Zhang Y. RNAi-mediated gene silencing in cancer therapy. Expert Opin Biol Ther 2012, 12:1495-1504.
48. Holmlund J.T. Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development. Ann N Y Acad Sci 2003, 1002:244-251.
49. Chen K.G., Sikic B.I. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 2012, 18:1863-1869.
50. Chiarini F., Del Sole M., Mongiorgi S., Gaboardi G.C., Cappellini A., Mantovani I., et al. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008, 22:1106-1116.
51. Xie X., Tang B., Zhou J., Gao Q., Zhang P. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep 2013, 30:773-782.
52. Barancík M., Bohácová V., Sedlák J., Sulová Z., Breier A. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 2006, 29:426-434.
53. Liu K.J., He J.H., Su X.D., Sim H.M., Xie J.D., Chen X.G., et al. Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. Int J Cancer 2013, 132:224-235.
54. Kim M., Gillies R.J., Rejniak K.A. Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front Oncol 2013, 3:278.
55. Choi I.K., Strauss R., Richter M., Yun C.O., Lieber A. Strategies to increase drug penetration in solid tumors. Front Oncol 2013, 3:193.
56. Ludescher C., Eisterer W., Hilbe W., Hofmann J., Thaler J. Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Br J Haematol 1995, 91:652-657.
57. Smith C.D., Zilfou J.T., Zhang X., Hudes G.R., Tew K.D. Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins. Cancer 1995, 75:2597-2604.
58. Braybrooke J.P., Vallis K.A., Houlbrook S., Rockett H., Ellmén J., Anttila M., et al. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol 2000, 46:27-34.
59. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
60. Teicher B.A. Tumor models for efficacy determination. Mol Cancer Ther 2006, 5:2435-2443.
61. Agarwal S., Manchanda P., Vogelbaum M.A., Ohlfest J.R., Elmquist W.F. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 2013, 41:33-39.
62. Martinez-Quintanilla J., Cascallo M., Gros A., Fillat C., Alemany R. Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy. Mol Cancer Ther 2009, 8:3098-3107.
63. Pastan I., Willingham M.C., Gottesman M. Molecular manipulations of the multidrug transporter: a new role for transgenic mice. FASEB J 1991, 5:2523-2528.
64. Licht T., Gottesman M.M., Pastan I. Transfer of the MDR1 (multidrug resistance) gene: protection of hematopoietic cells from cytotoxic chemotherapy, and selection of transduced cells in vivo. Cytokines Mol Ther 1995, 1:11-20.
65. Schinkel A.H., Mol C.A., Wagenaar E., van Deemter L., Smit J.J., Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995, 31A:1295-1298.
66. Aran J.M., Pastan I., Gottesman M.M. Therapeutic strategies involving the multidrug resistance phenotype: the MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy. Adv Pharmacol 1999, 46:1-42.
67. Chen C., Liu X., Smith B.J. Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr Drug Metab 2003, 4:272-291.
68. Schinkel A.H. Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther 1998, 36:9-13.
69. Lee J.J., Hughes C.S., Fine R.L., Page R.L. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 1996, 77:1892-1898.
70. Martinez M., Modric S., Sharkey M., Troutman L., Walker L., Mealey K. The pharmacogenomics of P-glycoprotein and its role in veterinary medicine. J Vet Pharmacol Ther 2008, 31:285-300.
71. Geyer J., Janko C. Treatment of MDR1 mutant dogs with macrocyclic lactones. Curr Pharm Biotechnol 2012, 13:969-986.
72. Fecht S., Distl O. Review of prevalence, genetic aspects and adverse effects of the mdr1-1Delta mutation in dogs. Dtsch Tierarztl Wochenschr 2008, 115:212-219.
73. MacEwen E.G. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990, 9:125-136.
74. Rutteman G.R., Erich S.A., Mol J.A., Spee B., Grinwis G.C., Fleckenstein L., et al. Safety and efficacy field study of artesunate for dogs with non-resectable tumours. Anticancer Res 2013, 33:1819-1827.
75. Volm M., Kästel M., Mattern J., Efferth T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 1993, 71:3981-3987.
76. Volm M., Mattern J. Resistance mechanisms and their regulation in lung cancer. Crit Rev Oncog 1996, 7:227-244.
77. Volm M., Koomägi R., Mattern J., Efferth T. Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 2002, 87:251-257.
78. Volm M., Koomägi R., Mattern J., Efferth T. Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin Cancer Res 2002, 8:1843-1848.
79. Volm M., Sauerbrey A., Zintl F., Koomägi R., Efferth T. Protein expression profile of newly diagnosed acute lymphoblastic leukemia in children developing relapses. Oncol Rep 2002, 9:965-969.
80. Volm M., Koomägi R., Efferth T., Mattern J. Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype. Anticancer Res 2002, 22:2321-2324.
81. Volm M., Koomägi R., Mattern J., Efferth T. Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases. Clin Exp Metastasis 2002, 19:385-390.
82. Volm M., Koomägi R. Prognostic relevance of angiogenic, proliferative, and apoptotic factors in lung carcinomas. A case review. Methods Mol Med 2003, 74:269-282.
83. Efferth T., Grassmann R. Impact of viral oncogenesis on responses to anti-cancer drugs and irradiation. Crit Rev Oncog 2000, 11:165-187.
84. Efferth T., Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005, 107:155-176.
85. Efferth T. Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products. Planta Med 2010, 76:1143-1154.
86. Jin J., Sun H., Wei H., Liu G. The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis. Invest New Drugs 2007, 25:95-105.
87. Efferth T. Molekulare Pharmakologie und Toxikologie 2006, Springer, Berlin, Heidelberg/New York.
88. Kiue A., Sano T., Naito A., Inada H., Suzuki K., Okumura M., et al. Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro. Jpn J Cancer Res 1990, 81:1057-1064.
89. Kiue A., Sano T., Suzuki K., Inada H., Okumura M., Kikuchi J., et al. Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents. Cancer Res 1990, 50:310-317.
90. Pommerenke E.W., Mattern J., Traugott U., Volm M. Durchbrechung der Multidrug-Resistenz mit (R)-Verapamil in vitro und in vivo. Arzneimittelforschung 1991, 41:855-858.
91. Pommerenke E., Mattern J., Volm M. Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo. J Cancer Res Clin Oncol 1994, 120:422-426.
92. Shen F., Chu S., Bence A.K., Bailey B., Xue X., Erickson P.A., et al. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 2008, 324:95-102.
93. Loor F., Boesch D., Gavériaux C., Jachez B., Pourtier-Manzanedo A., Emmer G. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance. Br J Cancer 1992, 65:11-18.
94. Keller R.P., Altermatt H.J., Nooter K., Poschmann G., Laissue J.A., Bollinger P., et al. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 1992, 50:593-597.
95. Watanabe T., Tsuge H., Oh-Hara T., Naito M., Tsuruo T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 1995, 34:235-241.
96. Warmann S.W., Heitmann H., Teichmann B., Gratz K.F., Ruck P., Hunger M., et al. Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma. Pediatr Hematol Oncol 2005, 22:373-386.
97. Shen F., Bailey B.J., Chu S., Bence A.K., Xue X., Erickson P., et al. Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells. J Pharmacol Exp Ther 2009, 330:423-429.
98. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993, 53:4595-4602.
99. Jansen W.J., Pinedo H.M., Kuiper C.M., Lincke C., Bamberger U., Heckel A., et al. Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole. Ann Oncol 1994, 5:733-739.
100. Sato W., Fukazawa N., Nakanishi O., Baba M., Suzuki T., Yano O., et al. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 1995, 35:271-277.
101. Naito M., Matsuba Y., Sato S., Hirata H., Tsuruo T. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin Cancer Res 2002, 8:582-588.
102. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996, 56:4171-4179.
103. Christensen J., Parks L., McNutt R., Leblanc G. Reversal of multidrug resistance by derivatives of acrivastine. Oncol Rep 1997, 4:1353-1360.
104. Desai P.B., Duan J., Sridhar R., Damle B.D. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole. Methods Find Exp Clin Pharmacol 1997, 19:231-239.
105. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001, 61:749-758.
106. Chen L.M., Liang Y.J., Ruan J.W., Ding Y., Wang X.W., Shi Z., et al. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J Pharm Pharmacol 2004, 56:1061-1066.
107. Peer D., Dekel Y., Melikhov D., Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 2004, 64:7562-7569.
108. Argov M., Kashi R., Peer D., Margalit R. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett 2009, 274:118-125.
109. Qi J., Wang S., Liu G., Peng H., Wang J., Zhu Z., et al. Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo. Biochem Biophys Res Commun 2004, 319:1124-1131.
110. Zalatnai A., Molnár J. Effect of SILA-409, a new organosilicon multidrug resistance modifier, on human pancreatic cancer xenografts. In Vivo 2006, 20:137-140.
111. Luo L., Xu X., Shi B., Wu J., Hu Y. Polyoxyethylene 40 stearate modulates multidrug resistance and enhances antitumor activity of vinblastine sulfate. AAPS J 2007, 9:E329-E335.
112. Fang W., Li Y., Cai Y., Kang K., Yan F., Liu G., et al. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo. J Pharm Pharmacol 2007, 59:1649-1655.
113. Dai C.L., Liang Y.J., Chen L.M., Zhang X., Deng W.J., Su X.D., et al. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochem Pharmacol 2009, 78:355-364.
114. Gyémánt N., Engi H., Schelz Z., Szatmári I., Tóth D., Fülöp F., et al. In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin. Br J Cancer 2010, 103:178-185.
115. Ganguly A., Banerjee K., Chakraborty P., Das S., Sarkar A., Hazra A., et al. Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative. Biomed Pharmacother 2011, 65:387-394.
116. Xu Y., Zhi F., Xu G., Tang X., Lu S., Wu J., et al. Overcoming multidrug-resistance in vitro and in vivo using the novel P-glycoprotein inhibitor 1416. Biosci Rep 2012, 32:559-566.
117. Zhao X.Q., Xie J.D., Chen X.G., Sim H.M., Zhang X., Liang Y.J., et al. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. Mol Pharmacol 2012, 82:47-58.
118. Chen M., Huang S.L., Zhang X.Q., Zhang B., Zhu H., Yang V.W., et al. Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem 2012, 113:2474-2487.
119. Zhou W.J., Zhang X., Cheng C., Wang F., Wang X.K., Liang Y.J., et al. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. Br J Pharmacol 2012, 166:1669-1683.
120. Hendrikse N.H., de Vries E.G., Eriks-Fluks L., van der Graaf W.T., Hospers G.A., Willemsen A.T., et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 1999, 59:2411-2416.
121. Christensen J.G., LeBlanc G.A. Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res 1996, 56:574-581.
122. Chou T.C., Depew K.M., Zheng Y.H., Safer M.L., Chan D., Helfrich B., et al. Reversal of anticancer multidrug resistance by the ardeemins. Proc Natl Acad Sci U S A 1998, 95:8369-8374.
123. Baggetto L.G., Dong M., Bernaud J., Espinosa L., Rigal D., Bonvallet R., et al. In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin. Biochem Pharmacol 1998, 56:1219-1228.
124. Fu L.W., Zhang Y.M., Liang Y.J., Yang X.P., Pan Q.C. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur J Cancer 2002, 38:418-426.
125. Zhu X., Sui M., Fan W. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res 2005, 25:1953-1962.
126. Wang F.P., Wang L., Yang J.S., Nomura M., Miyamoto K. Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells. Biol Pharm Bull 2005, 28:1979-1982.
127. Jin J., Wang F.P., Wei H., Liu G. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol 2005, 55:179-188.
128. Kim S.W., Kwon H.Y., Chi D.W., Shim J.H., Park J.D., Lee Y.H., et al. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol 2003, 65:75-82.
129. Fu L.W., He L.R., Liang Y.J., Chen L.M., Xiong H.Y., Yang X.P., et al. Experimental chemotherapy against xenografts derived from multidrug resistant KBv200 cells and parental drug-sensitive KB cells in nude mice by annonaceous acetogenin 89-2. Yao Xue Xue Bao 2003, 38:565-570.
130. Zhang C.J., Zhou G.Y., Li L., Ma L.L., Gao P., Li H. Reversal of multidrug resistance of MCF-7/ADR in nude mice by grape seed polyphenol. Zhonghua Wai Ke Za Zhi 2004, 42:795-798. [in Chinese].
131. Arora A., Seth K., Shukla Y. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis 2004, 25:941-949.
132. Qian F., Ye C.L., Wei D.Z., Lu Y.H., Yang S.L. In vitro and in vivo reversal of cancer cell multidrug resistance by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone. J Chemother 2005, 17(3):309-314.
133. Chou T.C., Guan Y., Soenen D.R., Danishefsky S.J., Boger D.L. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice. Cancer Chemother Pharmacol 2005, 56:379-390.
134. Huang M., Jin J., Sun H., Liu G.T. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol 2008, 62:1015-1026.
135. Ali M.M., Agha F.G., El-Sammad N.M., Hassan S.K. Modulation of anticancer drug-induced P-glycoprotein expression by naringin. Z Naturforsch C 2009, 64:109-116.
136. Oh W.K., Cho K.B., Hien T.T., Kim T.H., Kim H.S., Dao T.T., et al. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol Pharmacol 2010, 78:855-864.
137. Liang G., Tang A., Lin X., Li L., Zhang S., Huang Z., et al. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int J Oncol 2010, 37:111-123.
138. Zhang D.M., Shu C., Chen J.J., Sodani K., Wang J., Bhatnagar J., et al. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Mol Pharm 2012, 9:3147-3159.
139. Tang J., Fu Q., Wang Y., Racette K., Wang D., Liu F. Vitamin E reverses multidrug resistance in vitro and in vivo. Cancer Lett 2013, 336:149-157.
140. Starling J.J., Maciak R.S., Hinson N.A., Hoskins J., Laguzza B.C., Gadski R.A., et al. In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates. Cancer Res 1990, 50:7634-7640.
141. Pearson J.W., Fogler W.E., Volker K., Usui N., Goldenberg S.K., Gruys E., et al. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 1991, 83:1386-1391.
142. Rittmann-Grauer L.S., Yong M.A., Sanders V., Mackensen D.G. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res 1992, 52:1810-1816.
143. Sone S., Tsuruo T., Sato S., Yano S., Nishioka Y., Shinohara T. Transduction of the macrophage colony-stimulating factor gene into human multidrug resistant cancer cells: enhanced therapeutic efficacy of monoclonal anti-P-glycoprotein antibody in nude mice. Jpn J Cancer Res 1996, 87:757-764.
144. Hu X.F., Li J., Yang E., Vandervalk S., Xing P.X. Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. Br J Cancer 2007, 96:918-927.
145. Koziara J.M., Whisman T.R., Tseng M.T., Mumper R.J. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release 2006, 112:312-319.
146. Garcion E., Lamprecht A., Heurtault B., Paillard A., Aubert-Pouessel A., Denizot B., et al. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol Cancer Ther 2006, 5:1710-1722.
147. 4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo. Int J Nanomed 2009, 4:201-208.
148. Chen L.M., Liang Y.J., Zhang X., Su X.D., Dai C.L., Wang F.P., et al. Reversal of P-gp-mediated multidrug resistance by bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue. Anticancer Res 2009, 29:4597-4604.
149. van Vlerken L.E., Duan Z., Little S.R., Seiden M.V., Amiji M.M. Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J 2010, 12:171-180.
150. Gao Y., Chen L., Zhang Z., Chen Y., Li Y. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials 2011, 32:1738-1747.
151. Yin Q., Shen J., Chen L., Zhang Z., Gu W., Li Y. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(β-amino esters). Biomaterials 2012, 33:6495-6506.
152. Wang J., Sun J., Chen Q., Gao Y., Li L., Li H., et al. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials 2012, 33:6877-6888.
153. 4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomed 2012, 7:2261-2269.
154. Jin X., Mo R., Ding Y., Zheng W., Zhang C. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance. Mol Pharm 2013, [Epub ahead of print].
155. Cucco C., Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res 1996, 56:4332-4337.
156. Lopes de Menezes D.E., Hu Y., Mayer L.D. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice. J Exp Ther Oncol 2003, 3:72-82.
157. Shi Z., Liang Y.J., Chen Z.S., Wang X.W., Wang X.H., Ding Y., et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 2006, 5:39-47.
158. Mei Y., Shi Y.J., Ding X., Wu C.X., Jian H.G., Gong J.P., et al. Reversal of adriamycin resistance of hepatocellular carcinoma by targeting it with recombined adenovirus carrying antisense multidrug resistance gene 1 RNA. Zhonghua Gan Zang Bing Za Zhi 2007, 15:199-203. [in Chinese].
159. Xiao H., Wu Z., Shen H., Luo A.L., Yang Y.F., Li X.B., et al. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi. Basic Clin Pharmacol Toxicol 2008, 103:342-348.
160. Ren Y., Wang Y., Zhang Y., Wei D. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide-doxorubicin conjugate in vitro and in vivo. Mol Pharm 2008, 5:579-587.
161. Stein U., Walther W., Stege A., Kaszubiak A., Fichtner I., Lage H. Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol Ther 2008, 16:178-186.
162. Lu S., Huang Q., Wang Z., Song Y., Wang L. Reversal of multi-drug resistance by vector-based-shRNA-mdr1 in vitro and in vivo. J Huazhong Univ Sci Technol Med Sci 2009, 29:620-624.
163. Sun Y., Zhang T., Gao P., Meng B., Gao Y., Wang X., et al. Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs. Breast Cancer Res Treat 2010, 121:591-599.